Mostrar el registro sencillo del ítem

Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)

dc.rights.licenseopenen_US
dc.contributor.authorLE TOURNEAU, C.
dc.contributor.authorEVEN, C.
dc.contributor.authorSALAS, S.
dc.contributor.authorPOINTREAU, Y.
dc.contributor.authorCERUSE, P.
dc.contributor.authorBABIN, E.
dc.contributor.authorFAYETTE, J.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRONDEAU, Virginie
ORCID: 0000-0001-7109-4831
IDREF: 16662988X
dc.contributor.authorGRUMBERG, V.
dc.contributor.authorCOTTE, F. E.
dc.contributor.authorGOVART, A.
dc.contributor.authorBAUMSTARCK, K.
dc.contributor.authorGUIGAY, J.
dc.date.accessioned2024-01-22T13:19:10Z
dc.date.available2024-01-22T13:19:10Z
dc.date.issued2023-10
dc.date.conference2023-10-20
dc.identifier.issn0923-7534en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/187377
dc.description.abstractEnBackground ProNiHN is a prospective, observational, and multicenter study of patients (pts) with R/M SCCHN treated with nivo after progressing on or after platinum-based therapy. We report here the effectiveness and QoL for pts and their caregivers (cg). Methods Based on a minimum follow-up of 17-months (mo), progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meier method. QoL changes of pts were measured with 3 questionnaires (FACT-H&N & EQ-5D-3L&VAS) between inclusion (incl) and week-6, mo-3, 6, 12 and 18. QoL and needs of cg were estimated with CarGOQoL and SCNS-P&C-F questionnaires at incl and at 6 mo. Results Among 487 patients, median PFS and OS were 3.3 mo and 9.3 mo, respectively. OS rates were 64% at 6 mo, 40% at 12 mo and 28% at 18 mo. The number of pts completing FACT-H&N was 354 at incl and decreased to 39 at 18 mo. QoL of overall population tended to be stable or improved over time (Table). Same trend was observed for EQ-5D-3L&VAS. For pts (n=121) who completed FACT-H&N both at incl and 6 mo, overall total score significantly decreased (mean: -4.7; p=0.003), in particular for pts who stopped nivo within the 6 mo (-8.8; p<0.001) whereas it remained stable (0.0; p=0.986) for pts still on nivo. No significant difference was observed for pts (n=64) between incl and 12 mo (-2.4; p=0.291). 292 pts mentioned a cg, mostly spouse (71.4%). Among them, 48 cg completed CarGOQoL at incl and 6 mo. Psychological well-being improved over time (43.8 vs. 52.0; p=0.027) while relationship with healthcare decreased (62.0 vs. 53.1; p=0.045). FACT-H&N and CarGOQoL results were correlated at incl (0.226, p=0.003) and at 6 mo (0.362; p=0.006). Conclusions Nivo showed similar effectiveness and QoL in the real-world as in pivotal trial. QoL of pts tended to be stabilized over time, especially for patients still treated with nivolumab at 6 mo. QoL of cg and pts seems to be correlated.
dc.language.isoENen_US
dc.title.enNivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
dc.typeCommunication dans un congrèsen_US
dc.identifier.doi10.1016/j.annonc.2023.09.2082en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.pageS590-S590en_US
bordeaux.volume34en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issuesupplement 2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titleESMO Congress 2023en_US
bordeaux.countryesen_US
bordeaux.title.proceedingAbstract Book of the ESMO Congress 2023en_US
bordeaux.teamBIOSTAT_BPHen_US
bordeaux.conference.cityMadriden_US
bordeaux.identifier.funderIDBristol-Myers Squibben_US
hal.identifierhal-04409859
hal.version1
hal.date.transferred2024-01-22T13:19:13Z
hal.invitedouien_US
hal.proceedingsouien_US
hal.conference.organizerEuropean Society for Medical Oncologyen_US
hal.conference.end2023-10-24
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.date=2023-10&amp;rft.volume=34&amp;rft.issue=supplement%202&amp;rft.spage=S590-S590&amp;rft.epage=S590-S590&amp;rft.eissn=0923-7534&amp;rft.issn=0923-7534&amp;rft.au=LE%20TOURNEAU,%20C.&amp;EVEN,%20C.&amp;SALAS,%20S.&amp;POINTREAU,%20Y.&amp;CERUSE,%20P.&amp;rft.genre=unknown


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem